{"entity":{"id":"idea-prostate-randomise-the-sequence-not-only-the-drugs","kind":"idea","name":"Randomise the order of treatment, not only the drugs: a strategy platform for metastatic prostate cancer","aka":["sequencing trial prostate cancer","PFS2 strategy trial","treatment order randomised prostate"],"tldr":"Metastatic prostate cancer now has six classes of treatment that work, and no trial has ever compared the orders they can be given in. Every trial adds a drug to the front; none asks what should follow it, so the sequence a man receives is decided by habit and by what was licensed first.","summary":"Each of the classes was licensed against placebo or against an older drug, in a population defined by what it had already received: docetaxel against mitoxantrone, cabazitaxel after docetaxel, abiraterone and enzalutamide before and after chemotherapy, radium-223 in bone-predominant disease, lutetium-177 PSMA-617 after an androgen receptor drug and a taxane, and PARP inhibitors after progression on an androgen receptor drug. Intensification trials then moved several of them to the first day of metastatic diagnosis. What no trial has done is randomise the order.\n\nThat the order matters is not speculation. TRANSFORMER found identical progression-free survival on its primary endpoint and a difference of 8.6 months in progression-free survival through crossover depending on which arm came first, with a hazard ratio of 0.44. The same trial found prostate-specific antigen progression-free survival on enzalutamide was 3.8 months when it followed abiraterone and 10.9 months when it followed bipolar androgen therapy. CARD showed that switching from one androgen receptor drug to the other is worse than moving to cabazitaxel. The proposal is a standing platform in which the randomisation unit is a strategy rather than an agent, with progression-free survival through the second line as a co-primary endpoint alongside overall survival, and with re-randomisation at each progression. ProBio, which randomises by biomarker signature and adapts on outcome, is the nearest existing design; STAMPEDE2 has the infrastructure.\n\nWhat any of this means for someone treated in Britain, from the screening committee's position and the NICE appraisals to scanner and radiotherapy capacity, waiting times and how to reach a trial, is on the UK and NHS pathway page for prostate cancer.","asOf":"2026-09-25","links":[],"tags":["prostate-evidence"],"related":["idea-tr1-standing-platform-per-cancer","idea-tr1-smart-designs-for-adaptive-strategies","idea-bio1-alternating-schedules","prostate-roadmap","trial-modernisation-roadmap"],"cancers":["prostate","prostate-mhspc","prostate-mcrpc"],"sections":["hormonal","chemotherapy","radiopharma","targeted-therapy"],"technologies":["radioligand-therapy","psma-pet"],"targets":[],"drugs":["abiraterone","enzalutamide","docetaxel","cabazitaxel","pluvicto","radium-223","olaparib"],"companies":[],"institutions":[],"pathways":[],"terms":["radiographic-progression-free-survival","metastasis-free-survival","bipolar-androgen-therapy"],"trials":[],"people":[],"bottlenecks":["b-trial-design","b-combination-space","b-incentive-misalignment","b-funding-allocation","b-resistance"],"keyPapers":["paper-denmeade-transformer-bipolar-androgen-therapy-jco-2021","paper-de-bono-tropic-cabazitaxel-lancet-2010","paper-therap-lancet-2021","paper-vision-nejm-2021","paper-antonarakis-ar-v7-resistance-nejm-2014","paper-stampede-abiraterone-high-risk-attard-lancet-2022"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"In metastatic prostate cancer, the sequence in which the available treatment classes are given changes overall survival and time to the second progression by a margin comparable to that between the individual drugs, and a platform that randomises sequences with re-randomisation at progression can detect a difference of three months in progression-free survival through the second line within five years.","rationale":"Three lines of argument converge. Mechanistically, resistance to one androgen receptor drug is largely cross-resistance to the other, because both act on the ligand-binding domain and both select for AR-V7 and for lineage switching, whereas taxanes and radioligands do not; so an order that alternates mechanism should outlast one that does not. Empirically, TRANSFORMER measured a sequence effect of 8.6 months in PFS2 with quality of life favouring the same arm. Structurally, no regulator asks for sequence data and no company benefits from generating it, which is precisely the kind of question public platforms exist to answer. The alternative to running the trial is what happens now, which is that sequence is decided by licensing chronology.","test":"A publicly funded platform trial with sequence as the randomised unit: at metastatic castration-resistant progression, randomise between pre-specified two-step strategies (androgen receptor pathway inhibitor then taxane; taxane then androgen receptor pathway inhibitor; androgen receptor pathway inhibitor then radioligand where PSMA-positive; and in biomarker-positive men, PARP-containing strategies), with re-randomisation at the second progression. Co-primary endpoints: overall survival and progression-free survival through the second line. Stratify on homologous recombination repair status, PSMA uptake and prior hormone-sensitive intensification. Quality of life and time on treatment collected throughout. Five to seven years to first strategy comparison; reuse an existing platform rather than building new infrastructure.","maturity":"early-clinical","actor":"research","cost":"large","horizonYears":7},"route":"/ideas/idea-prostate-randomise-the-sequence-not-only-the-drugs/","neighbours":{"idea":[{"id":"idea-tr1-standing-platform-per-cancer","kind":"idea","name":"A standing platform trial for every major cancer, funded as infrastructure","route":"/ideas/idea-tr1-standing-platform-per-cancer/"},{"id":"idea-psma-pet-guided-mdt","kind":"idea","name":"PSMA-PET-guided metastasis-directed therapy as a curative strategy in oligorecurrent prostate cancer","route":"/ideas/idea-psma-pet-guided-mdt/"},{"id":"idea-bio1-alternating-schedules","kind":"idea","name":"Rotate between drugs on a fixed schedule instead of waiting for failure","route":"/ideas/idea-bio1-alternating-schedules/"},{"id":"idea-tr1-smart-designs-for-adaptive-strategies","kind":"idea","name":"SMART designs to test treatment strategies, not just single drugs","route":"/ideas/idea-tr1-smart-designs-for-adaptive-strategies/"}],"roadmap":[{"id":"prostate-roadmap","kind":"roadmap","name":"Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch","route":"/roadmaps/prostate-roadmap/"},{"id":"trial-modernisation-roadmap","kind":"roadmap","name":"Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on","route":"/roadmaps/trial-modernisation-roadmap/"}],"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate-mhspc","kind":"cancer","name":"Metastatic hormone-sensitive prostate cancer","route":"/cancers/prostate-mhspc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"chemotherapy","kind":"section","name":"Chemotherapy","route":"/fronts/chemotherapy/"},{"id":"hormonal","kind":"section","name":"Hormonal Therapy","route":"/fronts/hormonal/"},{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"drug":[{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/"},{"id":"cabazitaxel","kind":"drug","name":"Cabazitaxel","route":"/drugs/cabazitaxel/"},{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"},{"id":"radium-223","kind":"drug","name":"Radium-223 dichloride","route":"/drugs/radium-223/"}],"term":[{"id":"bipolar-androgen-therapy","kind":"term","name":"Bipolar androgen therapy (BAT)","route":"/terms/bipolar-androgen-therapy/"},{"id":"metastasis-free-survival","kind":"term","name":"Metastasis-free survival (MFS)","route":"/terms/metastasis-free-survival/"},{"id":"radiographic-progression-free-survival","kind":"term","name":"Radiographic progression-free survival (rPFS)","route":"/terms/radiographic-progression-free-survival/"}],"bottleneck":[{"id":"b-resistance","kind":"bottleneck","name":"Acquired resistance to every therapy","route":"/bottlenecks/b-resistance/"},{"id":"b-funding-allocation","kind":"bottleneck","name":"Funding follows fashion, not burden","route":"/bottlenecks/b-funding-allocation/"},{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/"},{"id":"b-combination-space","kind":"bottleneck","name":"Too many combinations to test","route":"/bottlenecks/b-combination-space/"},{"id":"b-trial-design","kind":"bottleneck","name":"Trial design, endpoints and cost","route":"/bottlenecks/b-trial-design/"}],"paper":[{"id":"paper-therap-lancet-2021","kind":"paper","name":"[ 177 Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","route":"/key-papers/paper-therap-lancet-2021/"},{"id":"paper-antonarakis-ar-v7-resistance-nejm-2014","kind":"paper","name":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","route":"/key-papers/paper-antonarakis-ar-v7-resistance-nejm-2014/"},{"id":"paper-stampede-abiraterone-high-risk-attard-lancet-2022","kind":"paper","name":"STAMPEDE: abiraterone with or without enzalutamide added to androgen deprivation for high-risk non-metastatic prostate cancer","route":"/key-papers/paper-stampede-abiraterone-high-risk-attard-lancet-2022/"},{"id":"paper-denmeade-transformer-bipolar-androgen-therapy-jco-2021","kind":"paper","name":"TRANSFORMER: bipolar androgen therapy versus enzalutamide in asymptomatic metastatic castration-resistant prostate cancer","route":"/key-papers/paper-denmeade-transformer-bipolar-androgen-therapy-jco-2021/"},{"id":"paper-de-bono-tropic-cabazitaxel-lancet-2010","kind":"paper","name":"TROPIC: prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel","route":"/key-papers/paper-de-bono-tropic-cabazitaxel-lancet-2010/"},{"id":"paper-vision-nejm-2021","kind":"paper","name":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer","route":"/key-papers/paper-vision-nejm-2021/"}]}}